Project Grant SB1HL184385
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $500K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boca Raton, FL 33431, USA
Similar Awards
- Federal Grant Award Summary Aventusoft LLC received a $500,000 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2025, with completion targeted for June 30, 2026. The award supports late-stage development and commercialization readiness activities for HATS-OFF (HemotTag Assessment for Short-Term Outcomes of Heart Failure), a non-invasive hemodynamic monitoring device designed to detect heart...
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute awarded $920,616 to Vena Vitals Inc. on September 24, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop VeriSleep, a wearable device for continuous, non-invasive blood pressure monitoring during sleep as a cardiovascular biomarker. The project addresses the technological gap in continuous blood pressure measurement during sleep, where current intermittent cuff-based monitors leave lengthy unmonitored gaps despite the...
- The National Heart, Lung, and Blood Institute awarded Pulsentry, Inc. $309,198 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and prototype an automated detection system for cardiac tamponade using existing fingertip pulse oximeters. Pulsentry will develop machine learning algorithms that analyze pulse waveform perturbations to identify early signs of cardiac tamponade, a medical emergency caused by fluid or clot accumulation around the heart...
- The National Heart, Lung, and Blood Institute awarded Texas A&M Engineering Experiment Station $706,159 on August 19, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a smart wearable continuous cuffless blood pressure, cardiac, and respiratory monitoring system agnostic to skin tone. The recipient will design and build an innovative wearable device integrating multiple non-invasive physiological sensors on the wrist to provide health-grade continuous...
- The National Heart, Lung, and Blood Institute awarded Actiox LLC $699,468 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) for development of a wearable microneedle-based biosensor for continuous cardiac troponin I monitoring. The assistance type is a Project Grant. Actiox will develop and optimize an electrochemical aptamer-based sensor integrated with microneedle arrays capable of real-time, ultra-sensitive monitoring of cardiac troponin I in interstitial...
- The National Heart, Lung, and Blood Institute awarded Environment & Health Group Inc. $314,321 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop HeartSense.AI, a generative AI-driven mobile health solution for hypertension self-management in lower-income adults. The application describes an mHealth platform that integrates a generative AI model with home-based blood pressure monitoring, digital pill reminders, and non-physician-led telehealth to...
- The National Heart, Lung, and Blood Institute awarded Autonomous Healthcare Inc. $305,999 on September 1, 2026, under the Small Business Innovation Research (SBIR) program to conduct a Phase I feasibility study of E-Fusion, a bedside clinical decision support system designed to assist anesthesiologists, anesthetists, and critical care nurses with vasopressor titration and blood pressure management during surgery and in the intensive care unit. The system monitors mean arterial pressure (MAP) and...
- The National Heart, Lung, and Blood Institute awarded $598,636 to Spheric Bio Inc. on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop the EMULAATE platform, a patient-specific left atrial appendage occlusion (LAAO) device for stroke prevention in atrial fibrillation patients. Spheric Bio is developing EMULAATE to assemble fully soft, personalized implants directly inside the patient's body through a minimally invasive approach by delivering,...
- The National Heart, Lung, and Blood Institute awarded Linshom Medical, Inc. $322,277 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct clinical evaluation of an alarm-activated detection system for early intervention of emerging respiratory decline using Linshom's FDA-cleared Continuous Predictive Respiratory Sensor (CPRS). The funding supports clinical development activities demonstrating the health economic value of the CPRS system, which...